

November 23, 2009

Immune Design Corp. Announces Appointment of Dr. Bruce L.A. Carter as Executive Chairman and Director

SEATTLE, Nov. 23 /PRNewswire/ -- Immune Design Corp. (IDC) announced today that Dr. Bruce L.A. Carter has joined IDC as Executive Chairman. Dr. Carter has a successful track record in biotechnology executive management. He was the former Chief Executive Officer at ZymoGenetics, in Seattle, WA and Chief Scientific Officer at Novo Nordisk, Copenhagen, Denmark.

(Photo: <http://www.newscom.com/cgi-bin/prnh/20091123/SF15228>)

Dr. Steven Reed, IDC's founder and Chief Executive Officer commented, "I am delighted to welcome Dr. Bruce Carter as a new member of IDC's management team and Board of Directors. His appointment and his broad biotech experience signifies our commitment to building a strong company that delivers on its scientific objectives. He is a great addition to IDC."

"With Dr. Steven Reed's expertise on vaccine adjuvants and Dr. David Baltimore's and Dr. Thomas Dubensky's expertise on the lentivirus-based vectors to introduce antigens to dendritic cells, IDC is poised to develop new improved vaccines to a world that desperately needs them," said Dr. Carter.

Dr. Carter possesses a unique combination of strong leadership skills and technical expertise in progressing healthcare products from the bench to the clinic, and ultimately to the people who need them.

Dr. Carter currently serves on the Board of ZymoGenetics, Dr. Reddy's Laboratories, the Hyderabad, India based generic drug maker, QLT, Inc. Vancouver, Canada and the nonprofit Global Alliance TB Drug Development Board, New York, NY. He joins IDC after a long career in the biotechnology and pharmaceutical arena.

Dr. Carter began his career in drug discovery at G. D. Searle. In 1986, he was appointed as V.P. and Head of Research & Development at ZymoGenetics. In 1994 he became a Corporate Executive V.P. at Novo Nordisk, as well as Chief Scientific Officer. In 2000, Dr. Carter led the negotiations that established ZymoGenetics as an independent company from Novo Nordisk and he became the CEO transforming the company from the research arm of a European company to a company that developed and commercialized Recothrom®.

IDC - Innovative Science

IDC's goal is to develop and commercialize new safe and effective vaccine products to prevent or target infectious and malignant diseases. IDC utilizes proprietary Toll-like receptor-4 agonist adjuvant and lentivirus-based vector platforms, which both target dendritic cells and are used to deliver antigens together with desired immunostimulatory signals.

For more information, go to www.immunedesign.com.

Contact:

Cassie Ostrander 206-826-7901 or
cassie.ostrander@immunedesign.com

SOURCE Immune Design Corp.

RELATED LINKS

<http://www.immunedesign.com>